FIFA Medical Assessment and Research Centre, and Schulthess Clinic, Zürich, Switzerland Correspondence to Mario Bizzini, FIFA Medical Assessment and Research Centre, FIFA-Strasse 20, P.O. Box, 8044 ...
A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study, in ...
GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback